Combination evidence
Cagrilintide + Retatrutide
Also called Cagri + Reta, Cagrilintide/Retatrutide stack
This pairing combines two investigational agents: cagrilintide (an amylin analogue) and retatrutide (a GIP, GLP-1 and glucagon receptor agonist). Neither is FDA-approved, and no human or animal study of the pair was found. Any rationale is theoretical.
Not studied together in humans
Components
What has been studied
- No human study of cagrilintide with retatrutide was found. Searched: PubMed (cagrilintide AND retatrutide; retatrutide AND amylin) and ClinicalTrials.gov (cagrilintide AND retatrutide: 0 records), October 2026. PubMed hits were reviews.
Why the pairing is discussed
Mechanistic reasoning drawn from studies of each component. Theoretical unless a study above tested the pair.
- Theoretical: cagrilintide is a long-acting amylin analogue that reduced body weight as monotherapy in a phase 2 trial 1.
- Theoretical: retatrutide is a single peptide with GIP, GLP-1 and glucagon receptor agonism; in obese mice, weight loss was attributed to GCGR-mediated energy expenditure added to GIPR- and GLP-1R-driven intake reduction 2. The pairing extrapolates the amylin-plus-incretin approach tested with semaglutide 3.
Concerns and unknowns
- Both agents cause dose-related gastrointestinal events on their own: cagrilintide in its phase 2 trial 1, and retatrutide in its phase 2 obesity trial, where gastrointestinal events were dose-related and dose-dependent heart-rate increases peaked at 24 weeks 4. Combined effects are unmeasured.
- No interaction, pharmacokinetic or safety data exist for the pair, and research-market products are not the trial materials.
- Cagrilintide has no Drugs@FDA application record 5; retatrutide is investigational and not FDA-approved.
- Neither is named on WADA's 2026 list; section S0 prohibits at all times any substance with no current governmental approval, such as drugs under clinical development 6.
Status of each component
| Compound | Regulatory status | Evidence | Half-life |
|---|---|---|---|
| Cagrilintide | Investigational | A | 159 to 195 hours (phase 1b, co-administered with s |
| Retatrutide | Investigational | A | Approximately 6 days (phase 1b multiple-ascending- |
Frequently asked questions
Has this combination been studied?
No study was found in humans or animals.
Are either of these drugs approved?
What is the main concern?
Both cause gastrointestinal adverse events on their own, and retatrutide raised heart rate in a dose-dependent way in phase 2 1 4. No data exist on combining them.
Is it permitted in sport?
References
- Once-weekly cagrilintide for weight management in people with overweight and obesity: a multicentre, randomised, double-blind, placebo-controlled and active-controlled, dose-finding phase 2 trial Lancet. 2021
- LY3437943, a novel triple glucagon, GIP, and GLP-1 receptor agonist for glycemic control and weight loss: From discovery to clinical proof of concept Cell Metab. 2022
- Efficacy and safety of co-administered once-weekly cagrilintide 2.4 mg with once-weekly semaglutide 2.4 mg in type 2 diabetes: a multicentre, randomised, double-blind, active-controlled, phase 2 trial Lancet. 2023
- Triple-Hormone-Receptor Agonist Retatrutide for Obesity: A Phase 2 Trial N Engl J Med. 2023
- Drugs@FDA application data queried through openFDA for cagrilintide (no matching application record returned, 23 Oct 2026) openFDA / Drugs@FDA. 2026
- International Standard: Prohibited List 2026 World Anti-Doping Agency. 2026